Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis

Upadacitinib and filgotinib, two JAK1 selective drugs have undergone extensive phase III clinical trials in RA and have demonstrated rapid improvements in disease activity, function and patient reported outcomes. Six global phase III randomized controlled clinical trials (SELECT phase III program) e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mysler, Eduardo, Lizarraga, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098104/
https://www.ncbi.nlm.nih.gov/pubmed/33950225
http://dx.doi.org/10.1093/rheumatology/keaa823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098104/
https://www.ncbi.nlm.nih.gov/pubmed/33950225
http://dx.doi.org/10.1093/rheumatology/keaa823

Ejemplares similares